A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

NCT05208281 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucopolysaccharidosis Type II
Metabolic Diseases

Interventions

DRUG: GNR-055 1.0-2.0-3.0 mg/kg
DRUG: GNR-055 2.0 mg/kg
DRUG: GNR-055 3.0 mg/kg

Sponsor

AO GENERIUM